Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045221 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,698
- Enrollment target
NCT06045221 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,698 participants.
The verdict
NCT06045221, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,698 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Interventions
- DRUG Orforglipron
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,698 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06045221
The ClinicalTrials.gov registry entry for NCT06045221 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,698 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Orforglipron is the first listed.
NCT06045221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06045221 about?
NCT06045221 is a clinical study titled "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin". The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
What is the current status of trial NCT06045221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,698 participants. The study started on 2023-09-22. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT06045221?
The interventions under investigation include: Orforglipron (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06045221?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.